• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Dr Jeroen Jansen Discusses Value-Assessment Questions Posed by Curative Treatments

Video

With the increasing prevalence of more expensive, potentially curative therapies, there comes the question of can we still afford expensive interventions that are that valuable, explained Jeroen Jansen, PhD, lead scientific advisor, Open-Source Value Project, Innovation and Value Initiative.

With the increasing prevalence of more expensive, potentially curative therapies, there comes the question of can we still afford expensive interventions that are that valuable, explained Jeroen Jansen, PhD, lead scientific advisor, Open-Source Value Project, Innovation and Value Initiative.

Transcript

Does the increasing prevalence of more expensive, potentially curative therapies warrant more novel ways of value assessment?

In principle, the increase in the number of treatments that can potentially cure does not necessarily change the methods of how we quantify the value. It simply becomes more of a question of not so much what’s the value of an intervention, but can we still afford expensive interventions that are that valuable. I think that’s the challenging question. So, it’s not so much, we have expensive interventions, do they need to be assessed differently? I don’t think that’s necessarily the question. The question is how are we going to afford all of these valuable interventions?

Related Videos
Stephen Speicher, MD, MS
dr dalia rotstein
dr marisa mcginley
Mila Felder, MD, FACEP
Leslie Busby, MD, Rocky Mountain Cancer Centers
Imran Khan, MD, PhD, Johnson & Johnson
Fabiola, Molina, MD, MHS | Image Credit: Yale School of Medicine
James Robinson, PhD, MPH, University of California, Berkeley
Patrick Vermersch, MD, PhD
dr daniel ontaneda
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.